Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Been here for a long time and I really hope this isn't doing a BMR....
Screen grabbed the abuse for years now... Today.... 1.25 Million Bought.... 9.79 Thousand Sold...
OF COURSE IT GOING DOWN NEARLY 4%?!?!?!?!?!?!
******S.
I hope the r-tards manipulating this share get completely fuk'd up.
If this goes BMR i may have a tantrum....
Ffs
Phytopharm PLC Interim Management Statement RNS Number : 4078M Phytopharm PLC 16 August 2011  16 August 2011 Interim Management Statement Phytopharm plc (PYM: London Stock Exchange) ("Phytopharm", the "Group" or the "Company") today issues its Interim Management Statement ("IMS") which relates to the period from 1 April 2011 to 16 August 2011 and contains information up to the date of publication of this IMS. Highlights for the period · Recruitment of patients with Parkinson's disease (PD) into the multi-national Cogane™ Phase II dose ranging study (CONFIDENT-PD) ongoing. · Achieved positive results demonstrating that Cogane™ reduced side effects associated with L-DOPA treatment in a preclinical model of PD; data presented at the Movement Disorders Conference in June 2011. · Positive preclinical in vitro data was presented at the World Glaucoma Congress in June 2011 supporting the ongoing development of Myogane™ in glaucoma. · United States Food & Drug Administration (FDA) granted Orphan Drug status to Cogane™ for the treatment of amyotrophic lateral sclerosis (ALS) in July 2011. Cogane™ in Parkinson's disease CoganeTM is currently being evaluated in a 400 patient multi-national Phase II, randomised, double blind, placebo controlled, dose ranging study (CONFIDENT-PD). The study has been designed to compare the safety, tolerability and efficacy of three doses of CoganeTM and placebo when administered for 28 weeks to untreated patients with early stage PD. Patient recruitment commenced in November 2010. Our target remains to have headline results from the study available at the end of 2012. A preclinical model conducted by Phytopharm has shown that administration of CoganeTM in conjunction with L-DOPA (the standard treatment for PD) resulted in improved control of symptoms compared to treatment with L-DOPA alone. We have also now demonstrated that CoganeTM reduced the side-effects of L-DOPA in preclinical models; this data was presented at the International Congress of Parkinson's disease and Movement Disorders held in June 2011 in Toronto, Canada. Together, these results demonstrate the potential of Cogane™ not only as a monotherapy for PD but also in combination with L-DOPA to widen the therapeutic window of L-DOPA. These data continue to support the development of CoganeTM as a new and potentially disease-modifying therapy for PD. In addition to its effects in preclinical models of PD CoganeTM has shown efficacy in preclinical models of cognitive impairment and therefore may have utility in treating the non-motor symptoms of PD. Cogane™ in motor neurone disease / ALS We have initiated a study of Cogane™ in the genetic "gold standard" in vivo model of ALS, with the support of the Motor Neurone Disease Association, a UK based charitable organisation